Shares of AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) fell 3% during mid-day trading on Monday . The stock traded as low as $26.70 and last traded at $26.88, with a volume of 355,229 shares traded. The stock had previously closed at $27.70.

Several research firms have recently issued reports on AMAG. Zacks Investment Research lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, April 29th. Leerink Swann reissued an “outperform” rating on shares of AMAG Pharmaceuticals in a report on Saturday, April 16th. Jefferies Group reissued a “buy” rating on shares of AMAG Pharmaceuticals in a report on Thursday, June 2nd. Raymond James Financial Inc. lowered AMAG Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 4th. Finally, Deutsche Bank AG reduced their target price on AMAG Pharmaceuticals from $42.00 to $35.00 and set a “hold” rating on the stock in a report on Monday, May 9th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $38.20.

The stock has a market capitalization of $910.44 million and a PE ratio of 88.06. The company’s 50-day moving average is $25.28 and its 200-day moving average is $23.69.

Several hedge funds have recently modified their holdings of the stock. Rhumbline Advisers raised its stake in shares of AMAG Pharmaceuticals by 10.1% in the fourth quarter. Rhumbline Advisers now owns 37,447 shares of the specialty pharmaceutical company’s stock valued at $1,131,000 after buying an additional 3,420 shares during the last quarter. Cornerstone Capital Management Holdings LLC. raised its stake in shares of AMAG Pharmaceuticals by 570.4% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 49,608 shares of the specialty pharmaceutical company’s stock valued at $1,498,000 after buying an additional 42,208 shares during the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of AMAG Pharmaceuticals by 6.6% in the fourth quarter. BNP Paribas Arbitrage SA now owns 62,716 shares of the specialty pharmaceutical company’s stock valued at $1,893,000 after buying an additional 3,903 shares during the last quarter. Finally, Bank of Montreal Can raised its stake in shares of AMAG Pharmaceuticals by 2,782.5% in the fourth quarter. Bank of Montreal Can now owns 75,781 shares of the specialty pharmaceutical company’s stock valued at $2,287,000 after buying an additional 73,152 shares during the last quarter.

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.